ReviewAutoimmunity2011
Therapeutic potential of TGF-β-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases.
Review in Autoimmunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- HIF-1α/NREP axis promotes hypertrophic scar fibroblast proliferation and collagen deposition via activation of the TGF-β1/Smad pathway.Biology direct · 2026Article
- Itreg cells Ameliorates MOG-induced brain inflammation via endowing DC tolerogenic capacity predominantly via TGF-beta signaling mediated AKT/mTOR pathway inhibition.Molecular medicine (Cambridge, Mass.) · 2025Article
- Review
- Mesenchymal stem cells and their exosomes mitigate osteoarthritis by restoring the balance between proinflammatory Teffs and Tregs.Frontiers in aging · 2024Review
- Cell-based therapies for the treatment of rheumatoid arthritis.Immunity, inflammation and disease · 2023Review
- The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives.Reviews in endocrine & metabolic disorders · 2022Review
- CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications.Biomedicines · 2022Review
- TGF-β-induced CD4+ FoxP3+ regulatory T cell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model.Cellular & molecular immunology · 2021Article
- MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies.Molecular & cellular proteomics : MCP · 2021Review
- Function and Role of Regulatory T Cells in Rheumatoid Arthritis.Frontiers in immunology · 2021Review
- Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.Advances in experimental medicine and biology · 2021Article
- CD4Cells · 2020Article
- Helminths protect against type 1 diabetes: effects and mechanisms.Parasitology research · 2019Review
- Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.Journal of neuroscience research · 2017Review
- Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.Inflammation · 2017Review
- Adoptive Cell Therapy of Induced Regulatory T Cells Expanded by Tolerogenic Dendritic Cells on Murine Autoimmune Arthritis.Journal of immunology research · 2017Article
- Progranulin Inhibits Human T Lymphocyte Proliferation by Inducing the Formation of Regulatory T Lymphocytes.Mediators of inflammation · 2017Article
- Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model.Frontiers in immunology · 2017Article
- CD4(+)CD25(-)Foxp3(+) T cells play a role in tuberculous hydrothorax rather than malignant hydrothorax.Journal of translational medicine · 2015Article
- Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells.Biomaterials · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Foxp3(+) T regulatory cell (Treg) subsets play a crucial role in the maintenance of immune homeostasis against self-antigens. The lack or dysfunction of these cells contributes to the pathogenesis and development of many autoimmune diseases. Therefore, manipulation of these cells may provide a novel therapeutic approach to treat autoimmune diseases. In this review, we provide current opinions concerning the classification, developmental, and functional characterization of Treg subsets. Particular emphasis will be focused on the therapeutic role of TGF-β-induced CD4M(+) Foxp3(+) cells (iTregs) in established autoimmune disease. Moreover, the similarity and diversity of iTregs and naturally occurring, thymus-derived CD4(+) CD25(+) Foxp3(+) regulatory T cells (nTregs) will be discussed, including the finding that the pro-inflammatory cytokine IL-6 can convert nTregs to IL-17-producing cells, whereas iTregs induced by TGF-β are resistant to the effects of this cytokine. Understanding these aspects may help to determine how Tregs can be used in the treatment of autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.